Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$1.75
0.116.71%
At close: Jan 21, 4:00 PM EST
$1.67
0.031.83%
Pre-Market: 4:00 AM EST
Comments
Loading...
Ovid Therapeutics Analyst Ratings and Price Targets | NASDAQ:OVID | Benzinga
Ovid Therapeutics Inc has a consensus price target of $3.84 based on the ratings of 11 analysts. The high is $7 issued by Ladenburg Thalmann on May 2, 2023. The low is $1.2 issued by Citigroup on June 18, 2024. The 3 most-recent analyst ratings were released by LifeSci Capital, HC Wainwright & Co., and Roth Capital on December 22, 2025, December 22, 2025, and December 11, 2025, respectively. With an average price target of $3 between LifeSci Capital, HC Wainwright & Co., and Roth Capital, there's an implied 79.64% upside for Ovid Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
LifeSci Capital
HC Wainwright & Co.
Roth Capital
Leerink Partners
BTIG
1calculated from analyst ratings
Analyst Ratings for Ovid Therapeutics
FAQ
What is the target price for Ovid Therapeutics (OVID) stock?
The latest price target for Ovid Therapeutics (NASDAQ:OVID) was reported by LifeSci Capital on December 22, 2025. The analyst firm set a price target for $4.00 expecting OVID to rise to within 12 months (a possible 139.52% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Ovid Therapeutics (OVID)?
The latest analyst rating for Ovid Therapeutics (NASDAQ:OVID) was provided by LifeSci Capital, and Ovid Therapeutics initiated their outperform rating.
When was the last upgrade for Ovid Therapeutics (OVID)?
The last upgrade for Ovid Therapeutics Inc happened on January 29, 2025 when Oppenheimer raised their price target to $4. Oppenheimer previously had a perform for Ovid Therapeutics Inc.
When was the last downgrade for Ovid Therapeutics (OVID)?
There is no last downgrade for Ovid Therapeutics.
When is the next analyst rating going to be posted or updated for Ovid Therapeutics (OVID)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ovid Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ovid Therapeutics was filed on December 22, 2025 so you should expect the next rating to be made available sometime around December 22, 2026.
Is the Analyst Rating Ovid Therapeutics (OVID) correct?
While ratings are subjective and will change, the latest Ovid Therapeutics (OVID) rating was a initiated with a price target of $0.00 to $4.00. The current price Ovid Therapeutics (OVID) is trading at is $1.67, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
